# Barbara Ann Karmanos Cancer Institute: Phase 2 study closed enrollment, 43 enrolled (Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Sponsor type | Academic and hospital |
| Study | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma |
| NCT ID | NCT03147885 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Diffuse Large B-Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma |
| Intervention types | drug |
| Target enrollment | 43 |
| Site countries | United States |
| Posted | 2017-05-10 |
| Planned start | 2017-06-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03147885). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.